Navigation Links
FDA Orders Halt to Marketing of Unapproved Single-Ingredient Oral Colchicine
Date:9/30/2010

SILVER SPRING, Md., Sept. 30 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today took action against companies that manufacture, distribute, and/or market unapproved single-ingredient oral colchicine, a medication commonly used for the daily prevention of gout, to treat acute gout flare-ups, and for the treatment of Familial Mediterranean Fever (FMF).

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

The companies are expected to stop manufacturing single-ingredient oral colchicine within 45 days and must stop shipping this unapproved product in interstate commerce within 90 days. A small amount of unapproved colchicine is expected to be available after these dates until supplies are exhausted.

Many single ingredient oral colchicine products have been used by the medical community for decades. These and a variety of other medications have not received the mandatory modern-day FDA-approval required of all prescription drugs.

Colcrys is the only FDA-approved single-ingredient oral colchicine product available on the U.S. market. Approved by the FDA in 2009, Colcrys' prescribing information contains important safety data and recommendations on drug interactions and dosing not available with unapproved products.

The manufacturer of Colcrys, Mutual Pharmaceutical/URL Pharma, has established a Patient Assistance Program (PAP) and a Co-Pay Assistance Program (CAP) to ensure that all patients will be able to continue affordable access to colchicine. The company also has informed FDA that it will maintain the programs at a minimum until there is FDA-
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
2. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
3. Hyperion Therapeutics Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of GT4P in Patients With Urea Cycle Disorders
4. Mayo Clinic Physicians Report Findings from Research on Sleep Disorders
5. Bristol-Myers Squibb, New Jersey Childrens Hospital Launch Center for Immune System Disorders & Infectious Diseases Including HIV/AIDS
6. Study Finds Fever may Lead to Improved Behavior in Children with Autism Spectrum Disorders
7. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
8. MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders
9. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
10. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
11. Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014  ConvaTec, a privately-held medical products and ... appointed Interim Chief Executive Officer of the company, effective ... Ken Berger .  "The Board of Directors of ConvaTec ... over the past three years," said Magnus Lundberg ... are confident that the company is well positioned for ...
(Date:12/22/2014)... 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: ... discovering, developing and commercializing innovative therapies addressing major ... the following open letter to shareholders from President ... Sc. Dear RXi Shareholders, ... inaccurate statements posted on certain social media sites ...
(Date:12/22/2014)... , Dec. 22, 2014  Pfenex Inc. (NYSE ... recombinant anthrax vaccine, has been filed and is now ... provided by the Department of Health and Human Services ... (BARDA). "We are extremely pleased to have ... Px563L.  This represents a significant milestone in our company,s ...
Breaking Medicine Technology:ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 3
... September 30 Gamida Cell announced,today the publication of ... widely known as "StemEx", as a therapy for blood ... ex vivo expanded,umbilical cord blood cell graft for allogeneic ... Petropoulos, will be published in the,November 2009 issue of ...
... 30 GenVec, Inc. (Nasdaq: GNVC ) announced today ... and Research (SBIR) grant from the National Cancer Institute (NCI) ... research of a new approach to treating metastatic cancer. Under ... hypothesis that the delivery of a specific gene will stimulate ...
Cached Medicine Technology:Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for Leukemia and Lymphoma 2Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for Leukemia and Lymphoma 3GenVec Receives National Cancer Institute Grant to Expand Cancer Program 2
(Date:12/24/2014)... Mike Billings , PT, MS, CEEAA, President ... PT, MBA, GCS, Director of Professional Development to discuss ... of the Improving Medicare Post-Acute Care Transformation Act ... the Infinicast, the two leaders discuss how the IMPACT ... to standardize post-acute assessment data for quality, payment, and ...
(Date:12/24/2014)... Dennis Thompson HealthDay Reporter ... bisexual men who have abstained from sex for one year will ... new federal policy that would reverse a 31-year ban on donations ... and Drug Administration announced Tuesday its intention to release a new ... to blood donations from gay men. The FDA is changing ...
(Date:12/24/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- Hepatitis C infection ... according to a new study. Treatment advances have made ... but many develop memory and thinking problems, mood swings and ... authors said. It,s believed that long-term infections with other ... may affect the brain. One of the prime suspects has ...
(Date:12/24/2014)... 2014 (HealthDay News) -- Adults who experienced childhood ... migraine headaches, suggests a study published online Dec. ... "Childhood maltreatment can have long-lasting effects, like associated ... study author Dawn Buse, director of behavioral medicine ... said in a journal news release. "When ...
(Date:12/24/2014)... Haelle HealthDay Reporter ... more likely to start smoking or drinking with each ... or conduct disorder, new research suggests. "Our ... risk of substance use as [these] children approach adolescence," ... Cincinnati Pediatric Research Group, which is part of Cincinnati ...
Breaking Medicine News(10 mins):Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3Health News:Hepatitis C Infection Isn't Related to HIV Brain Woes: Study 2Health News:Abuse in Childhood Tied to Migraines in Adulthood 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3
... announced a computer network for the NHS, that would cost ... with a consortium of IT companies comprising of Atos Origin, ... and,will provide the NHS with national computer services for 11 ... health service payroll and nurse rosters. ,The consortium ...
... a rather unique show of exemplary medical prowess and ... John Hopkins //Comprehensive Transplant Center. This maiden feat was ... and 18 nurses and it took place over 10 ... the hospital has confirmed the good health of the ...
... research featured at ACP Foundation's Health Literacy Conference reports ... patient errors. //Most often, patients could not explain why ... much or how often should they take them. ... health literacy – says the research. ,Low ...
... increase the chances of heart attack, but cocaine lifts the ... study reported that ‘while sex causes very little increased risk ... 20-folds’. ,The review by University of Sydney and ... attacks, including sexual activity, cocaine use, pollution, heavy meals, and ...
... the risk of dementia according to recent research. // ... lower risk of dementia and Alzheimer’s disease. ,DHA or ... factor that is required for the proper functioning of the ... month’s issue of the Archives or Neurology. ,According to ...
... reported from strife-torn Afghanistan, have grown from a manageable 8 ... raised concern amongst health authorities as a significant cause of ... ,Anti-narcotics Minister Mohammad Zafar explained how the number of heroin ... to 14,000 in 2005. , ,'Forty to 50 percent ...
Cached Medicine News:Health News:Maiden Quintuple Kidney Transplant Sets a Record 2Health News:Low Health Literacy Is The Major Cause For Patient Errors 2
... This Sarmiento style Patella-Tendon-Bearing brace is designed ... the tibia and fibula. The tibial crest ... intra medullary nailing and removal of internal ... movement of joints above and below the ...
Designed as an excellent form of primary suspension...
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... This lightweight orthosis is designed to ... joint while allowing unobstructed motion of ... more custom fit the splint may ... formed using a heat gun. One ...
Medicine Products: